Analysts are holding steady at 6 bullish to 0 bearish.
4 YouTube analysts cover JOHNSON & JOHNSON (JNJ).
What do YouTube analysts say about JNJ?
4 YouTube finance analysts have published research on JOHNSON & JOHNSON (JNJ). Across their latest videos, their tracked takes split 6 bullish to 0 bearish, so the coverage reads as stable rather than a single consensus call. TickerReceipts groups every tracked take by stance and links each one back to the exact moment in the source video, so you can hear the argument in the analyst’s own words instead of a summary. The sharpest split right now is over Where do analysts disagree on JNJ?. None of this is our opinion or a price target: it is a synthesis of what independent YouTube analysts have actually said about JNJ, organized so you can weigh the bull and bear cases side by side and decide for yourself.
100% SENTIMENT
stable
AS OF MAY 8
Where do analysts disagree on JNJ?
The clearest disagreement among YouTube analysts covering JOHNSON & JOHNSON (JNJ) is over Where do analysts disagree on JNJ?. 6 tracked takes argue the bull side and 0 the bear side, and we keep both cases on the same page with the video receipt behind each one. We do not pick a winner or resolve the debate for you: each side links to the exact timestamp where the analyst makes the claim, so you can judge the reasoning yourself. Where an analyst has changed their stance over time, that flip is recorded too. The point of JNJ’s debate view is not to tell you who is right, but to surface the strongest version of each argument from independent YouTube research, side by side, with sources you can check.
What's the latest research on JNJ?
The most recent research on JOHNSON & JOHNSON (JNJ) comes from 4 YouTube finance analysts, currently split 6 bullish to 0 bearish. Each take below is a receipt: the analyst’s claim, the stance we tagged it with, and a link to the exact moment in the source video. We surface tier-1 analyst opinions first, then official filings and other context as that data lands. Nothing here is generated or paraphrased into a house view — it is the actual YouTube research that exists on JNJ, organized newest-first and by debate. Use it to catch up on what credible independent voices are saying, see where they line up and where they clash on Where do analysts disagree on JNJ?, and follow any claim back to its source before you act on it.
JNJ’s growth reacceleration improves quality, but Forecaster fair value of ~$216–$217 still leaves it ~6% overvalued versus a dividend-growth scenario.
JNJ’s mix shift into innovative medicine and reaccelerating earnings growth supports the turnaround, but valuation has expanded. Forecaster’s average fair value around $216–$217 implies about 6% overvalued, and the uncertainty risk remains for cash flows tied to pharmaceutical revenue.
JNJ is the kind of blue-chip dividend business that can be “safe” within a diversified portfolio because it should keep producing income, even though any single company can still face litigation or other shocks.
Johnson & Johnson is framed as a reliable blue-chip dividend holding within a diversified portfolio, with durable healthcare cash flows expected to sustain income even under litigation or macro shocks. Its defensive characteristics make it a core candidate for the stable side of a dividend barbell.
Publish-day $227.19 · 05/02
"Dividend Barbell Portfolio: A Smarter Strategy for Stronger Income"
Johnson & Johnson (JNJ) earns a place in my portfolio for stability of shareholder payouts, paying roughly $5,200 per year on my ~$226k position.
Johnson & Johnson contributes about $5,200 per year on a ~$226k position, valued for payout stability rather than growth. The healthcare dividend profile fits a defensive, income-oriented portfolio construction.
Publish-day $227.50 · 04/25
"How much my $3,770,749 Dividend Portfolio Makes Per Year"
No official filings surfaced for JNJ yet.
How has sentiment changed over time?
Sentiment on JOHNSON & JOHNSON (JNJ) is not a static number — it moves as analysts publish, revise, and occasionally reverse their calls. The current balance is 6 bullish to 0 bearish, and the broader trend reads as stable. TickerReceipts records every stance change over time so you can see whether today’s split is a fresh shift or a long-standing standoff, and which analysts moved. The free view shows the current balance and the latest direction; the full stance timeline, each analyst’s track record, and how the Where do analysts disagree on JNJ? debate evolved are part of the time dimension. We never invent momentum: when there is no prior snapshot to compare, we say so rather than fabricate a trend.
100% SENTIMENT · stable
Is JNJ a buy according to YouTube analysts?
Who covers JNJ on YouTube?
4 independent YouTube finance analysts have published tracked research on JOHNSON & JOHNSON (JNJ). Each of their takes links back to the exact moment in the source video.
Are YouTube analysts bullish or bearish on JNJ?
Across tracked takes, 6 are bullish on JNJ and 0 bearish — from 4 analysts in total. TickerReceipts shows both sides side by side rather than a single rating.
Does TickerReceipts recommend buying JNJ?
No. TickerReceipts publishes no ratings, price targets, or advice. We synthesize what independent YouTube analysts have said about JNJ so you can weigh the research yourself.
